Active Ingredient(s): Acalabrutinib
FDA Approved: * October 31, 2017
Pharm Company: * ACERTA PHARMA BV
Category: Cancer

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).[4] It may be used both in relapsed as well as in treatment-naive settings.[5] Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells.[4] It is a second genera... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Calquence 100 mg Oral Capsule, Gelatin Coated
NDC: 0310-0512
Astrazeneca Pharmaceuticals Lp
Calquence 100 mg Oral Tablet, Film Coated
NDC: 0310-3512
Astrazeneca Pharmaceuticals Lp